GlassScriptPhysician profile
Joseph Niezer
NPI 1538509476
$2,555.35
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,515 · 2020: $632 · 2021: $112 · 2022: $49.93 · 2023: $205 · 2024: $42.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $241 · Education: $5.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $241.35 |
| Education | $5.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $554.94 | 2019-2020 | |
| Allergan, INC. | $423.68 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $235.48 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $182.84 | 2023-2024 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $151.66 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $121.85 | 2019-2023 | Ingrezza |
| Lundbeck LLC | $113.66 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $111.32 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $102.81 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $86.68 | 2019-2020 | |
| Tris Pharma INC | $72.03 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $65.28 | 2021-2023 | |
| Abbvie INC. | $61.01 | 2021-2023 | |
| Bausch Health US, LLC | $51.72 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $45.42 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $41.05 | 2019-2020 | |
| Shire North American Group INC | $34.79 | 2019 | |
| Neos Therapeutics, LP | $31.50 | 2019 | |
| Vertical Pharmaceuticals, LLC | $19.18 | 2020 | |
| Pernix Therapeutics Holdings, INC. | $19.08 | 2019 | |
| Axsome Therapeutics, INC. | $15.03 | 2023 | Auvelity |
| Corium, LLC | $14.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Niezer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.